T-AYU- HM Premium Anti-Sickling Medicine for Management of Sickle - - PowerPoint PPT Presentation

T-AYU-HM™ Premium

Anti-Sickling Medicine for Management of Sickle Cell Anemia.

Sicklecare TAYUHM Limited.

Improving Quality of Life…

T-AYU-HM™ Premium

Composition: Each T-AYU-HMTM Premium tablet (300 mg) contains:

1 Calyx of Mica 25mg 2 Calyx of Iron 12.5mg 3 Terminala chebula 25mg 4 Zingiber officinale 25mg 5 Asparagus racemosus 25mg 6 Punica granatum 12.5mg 7 Myristica fragrans 25 mg 8 Piper longum 37.5 mg 9 Tinospora cordifolia 37.5 mg 10 Leptadinia reticulate 37.5 mg

In-Vitro RBC Sickling (Emmel’s Test) Results

The morphology of Sickle Cells that were incubated under anaerobic conditions in the absence

• r

presence of various concentration of T- AYU-HM™ Premium compared to 10mM Vanillin (4-Hydroxy-3- methoxybenzaldehyd e) for 24 hour.

• Ve Control

+ Ve Control 10 mM Vanillin as standard 25 µg/ml T-Ayu-HM™ Pre 50 µg/ml T-Ayu-HM™ Pre 100 µg/ml T-Ayu-HM™ Pre

In-Vitro RBC Sickling (Emmel’s Test) Results

• Ve Control

+ Ve Control 10 mM Vanillin as standard 25 µg/ml T-Ayu-HM™ Pre 50 µg/ml T-Ayu-HM™ Pre 100 µg/ml T-Ayu-HM™ Pre 500 µg/ml T-Ayu-HM™ Pre

In-Vitro RBC Sickling (Emmel’s Test) Results

5

* * * * * 10 20 30 40 50 60 70 80 90 100 control 10 mM vanillin stardard 25 µg/ml HMP 50 µg/ml HMP 100 µg/ml HMP 500 µg/ml HMP % Sickled Cells

Percent of Sickled cells in presence of T-AYU-HM™ Premium

n=5, * p<0.05 as compared to control samples Treatment Control (PBS) 10 mM Vanillin 25 µg/ml T-Ayu-HMP 50 µg/ml T-Ayu-HMP 100 µg/ml T-Ayu-HMP 500 µg/ml T-Ayu-HMP % Sickle Cells (Mean ± SD)

67.94 ± 4.47 24.07 ± 10.66 55.22 ± 4.66 44.28 ± 5.77 39.34 ± 5.90 27.41 ± 8.12

% Inhibition

• f sickling

(Mean ± SD)

• 64.62

± 15.41 18.32 ± 10.11 34.51 ± 10.21 41.83 ± 10.33 59.85 ± 11.36

In-Vitro RBC Sickling (Emmel’s Test) Results

Treatment Control (PBS) 10 mM Vanillin 25 µg/ml T-Ayu-HMP 50 µg/ml T-Ayu-HMP 100 µg/ml T-Ayu-HMP 500 µg/ml T-Ayu-HMP % Sickle Cells (Mean ± SD)

67.94 ± 4.47 24.07 ± 10.66 55.22 ± 4.66 44.28 ± 5.77 39.34 ± 5.90 27.41 ± 8.12

% Inhibition

• f sickling

(Mean ± SD)

• 64.62

± 15.41 18.32 ± 10.11 34.51 ± 10.21 41.83 ± 10.33 59.85 ± 11.36

Oxidative Hemolysis of Sickle Red Blood Cells

• 10.00

0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 15 30 45 60 75 90 105 120 Percent Haemolysis Time in Min

Control 50 ug/ml T-Ayu-HM 100 ug/ml T-ayu-HM 500 ug/ml T-ayu-HM

0.00 10.00 20.00 30.00 40.00 50.00 60.00 70.00 80.00 90.00 100.00 Control 50 ug/ml T- Ayu-HM 100 ug/ml T- ayu-HM 500 ug/ml T- ayu-HM Methaemoglobin (%)

t-BOOH induced Formation of Methaemoglobin at 12 Hr

* indicates significantly different means from the control groups (P<0.05) analyzed by one-way ANOVA followed by Dunnett's comparison test

* *

Membrane Stabilization Activity by Osmotic Fragility Test

0.00 20.00 40.00 60.00 80.00 100.00 120.00 0.00 0.20 0.40 0.60 0.80 1.00 Percentage Haemolysis Concentration of NaCl Solution control (PBS) 50 µg/ml T-Ayu-HM 100 µg/ml T-Ayu-HM 500 µg/ml T-Ayu-HM 10 mM Vanillin 0.45 0.47 0.49 0.51 0.53 0.55 0.57 0.59 control (PBS) 10 mM Vanillin 50 µg/ml T- Ayu-HM 100 µg/ml T-Ayu-HM 500 µg/ml T-Ayu-HM

• Conc. of NaCl

Concentration at Haemolysis 50%

Stasis Induced Venous Thrombosis in SD Rats

1 2 3 4 5 6 7 8 9 10

Vehical Control 30 mg/ kg Aspirin 100 mg/kg T-AYU-HM 300 mg/kg T-AYU-HM 500 mg/kg T-AYU-HM

Weight of Throbis (mg)

Stasis Induced Venous Thrombosis in SD Rats

n=5, * p<0.05 as compared to control samples using Student’s t test

* * *

Conclusion

• The ability of T-AYU-HM Premium to normalize the sickle erythrocytes

may represent a rational explanation for the use in treating sickle cell anemia.

• Sickled RBCs showed a lesser degree of t-BOOH-induced haemolysis in

treatment group than control groups and were more resistant to t-BOOH induced hemolysis.

• T-AYU-HM Premium causes stabilization of the erythrocytes membrane,

reflected in the decrease in osmotic fragility values.

• T-Ayu-HM premium significantly shows decrease in thrombus formation.
• The present investigation provides evidence to support the claims of the

herbomineral formulation for treatment and management of sickle cell anemia

Discussion

• Literature survey revealed that herbomineral formulations

include various plant extracts and minerals which can be useful in the complications of sickle cell disease. For instance,

• Zingiber officinale contains essential oil which possess anti-

inflammatory activity (Thomson et al., 2002).

• Punica

Granatum containing brevifolin carboxylic acid, brevifolin, 7,8-Dihydroxycoumarin 7-Ellagic acid are known to posses anti-oxidant and analgesic activities (Singh et al., 2002, Nawwar et al., 1994, Hussein et al., 1997).

• Myristica

Fragrans shows potent antiplatelet activity, Antioxidant activity (Duan et al., 2009)

Discussion

• Piper

longum shows inhibitory activity

• n

platelet aggregation induced by collagen, arachidonic acid, and platelet-activating factor (Park et al., 2007),

• Terminalia Chebula shows antioxidant properties , contains

polyphenolic compounds like casuarinin, chebulanin, chebulinic acid or 1,6-di-O-galloyl-β -D-glucose (Cheng et al., 2003).

• Asparagus

racemosus shows cytoprotective activity (Dahanukar et al., 1983) as well as antioxidant activity (Kamat et al., 2000),

• Mica Ash useful in anemia, splenomegaly (Desai, 2008), aging

and general debility,

• Iron Ash used in treatment of iron deficiency anaemia

(Pandit et al., 1999).

Application

• T-Ayu-HM™ Premium is being used in India by proficient Practitioners for the

treatment of sickle cell anemia

• Dramatic improvements in the patients conditions were observed with respect to

Reduction or freedom from symptoms

 Hand & Chest syndrome  Avascular necrosis of femur (AVNF)  Relief from pain  Splenomegaly, jaudice, pallor, backache, abdominal colic, loss of appetite, and headache.  Improvement in hematological parameters  Need for Blood transfusions is also considerably reduced.

Summary of overall relief

 It improves quality of life of the patient  It improves general conditions of the patient  It drastically reduces the need for repeated blood transfusions.  It normalizes renal and liver functions  it eliminates the need for splenectomy  it strengthens the cardiac functions  it eliminates chronic fatigue; patients feel more energetic  it prevents kidney damage due to the disease  it prevents formation of gall stones  it improves RBC function  it consists of a balanced mixture of time-tested and safe herbominerals without any side effects  it is manufactured as per FDA standards  Each ingredient is subjected to physical and chemical analysis  Its formulation is subjected to Heavy Metal Microbial testing  Its safety for human use is ascertained by LD50 values

Dosage

• 2 tablets daily (Morning and Evening) or as

directed by physician for HbSS.

• In severe condition 2 tablets twice daily for 120

days for HbSS.

• During Crisis 2 tablets twice daily with lifesavers

medications.

• 1 tablet daily (Morning and Evening) for HbAS.
• 2 tablets daily for complications of HbAS.

Warning : pregnant women, nursing mothers and children under 5 years have to be prescribed by the attending doctors.

Indications

• INDICATIONS AND USAGE: T-AYU-HM ™ Premium tablets are indicated mainly for sickle cell anemia

.The product is also useful in other types of anemia

• CONTRA INDICATIONS: T-AYU-HM ™ Premium tablets are contraindicated during pregnancy and

lactation .

• WARNING AGAINST MISUSE: T-AYU-HM ™ Premium is indicated for a specific condition called sickle

cell anemia and should be used as per the dosage recommended by the manufacturer; should not be used for conditions not recommended by the manufacturer.

• PRECAUTIONS: During the use of T-AYU-HM ™ Premium tablets, patients have to be carefully
• bserved and any untoward reactions to be reported immediately to the attending Physician. Patients

have to be carefully and continuously monitored by the attending Physician during the T-AYU-HM ™ Premium therapy. In severe cases of Sickle cell anemia there could be additional need for measures, medications, blood transfusions and even hospitalizations-which should be promptly resorted to.

• DOSAGE AND ADMINISTRATION: 2 tablets of 300mg twice a day or as directed by the Physician.
• ADVERSE REACTIONS: No specific adverse reaction was reported in patients who have used T-AYU-

HM ™ Premium

• DRUG ABUSE AND DRUG DEPENDENCE: T-AYU-HM ™ Premium Tablets contain time tested herbal

and Ayurvedic ingredients. There is no propensity to cause drug abuse and drug dependence. There is no report of drug abuse or drug dependence.

• SYMTOMS OF OVERDOSAGE AND ANTIDOTE: None.

References

• P.T. Mpiana, D.S. Tshibangua, O.M. Shetondea, K.N. Ngboluab “In vitro antidrepanocytary actvity

(anti-sickle cell anemia) of some congolese plants”, Phytomedicine, 14, (2007), 192–195.

• E. Iyamu, E. Turner and T. Asakura, “In vitro effects of NIPRISAN (Nix-0699): a naturally occurring,

potent antisickling agent” British Journal of Haematology, 118, 2002, 337–343J.

• O. Moody, O. O. Omotade, A. A. Adeyemo, “ Anti-sickling Potential of a Nigerian Herbal Formula

(Ajawaron HF) and the Major Plant Component (Cissus populnea L. PK) ” Phytother Res. 17, (2003), 1173–1176.

• Gorecki et al., “Antisickling activity of amino acid benzyl esters” Proc. Natl. Acad. Sci.USA

Biochemistry ,1980,77(1), 181-185

• Iheanyichukwu elekwa, Michael monanu, Emmanuel anosike “In vitro effects of aqueous extracts
• f Zanthoxylum macrophylla roots on adenosine triphosphatases from human erythrocytes of

different genotypes” BIOKEMISTRI 17, 1, 2005 :19-25.

• Stuart M.J., Nagel R.L., Sickle-cell disease. Lancet. 2004;364:1343-1360
• Steinberg M.H., Pathophysiologically based drug treatment of sickle cell disease. Trends in

Pharmacological science. 2006;27:204-210

• Herfindol E.T., Gourley D.R., Text book of Therapeutics Drug and Disease Management.7th

edi.,2001,251-254.

• Kate S. L., Lingojwar D. P., Epidemiology of Sickle Cell Disorder in the State of Maharashtra. Int J

Hum Genet.2002;2:161-167

• Gupta R.B., Sickle cell disease loads in Madhypradesh. RMRCT update, 2006;3:1-8
• Balgir R.S., Epidemiology, Population Health Genetics and Phenotypic Diversity of Sickle Cell

Disease in India. The Internet Journal of Biological Anthropology . 2007;1:2

Q&A…

Thank you for your attention Sicklecare TAYUHM Limited.

16, Adeyemi Lawson Street, Off Queens drive, Ikoyi Lagos, Nigeria. +2348106910220.